You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
招商局中國基金(00133.HK)斥800萬美元認購Immvira的1.6%股權
阿思達克 09-30 12:22
招商局中國基金(00133.HK)公布,全資附屬公司星群簽訂Immvira Bioscience Inc.的優先股認購協議,出資800萬美元認購Immvira所發行的優先股,交易完成後星群將通過認購優先股擁有Immvira約1.6%的已發行總股本。 Immvira主要從事將載體技術作為潛在癌症療法的臨床研發,專注開發新一代原創抗腫瘤藥物載體,包括複製和非複製型皰疹病毒載體、外泌體遞送載體以及抗腫瘤疫苗。 公司認為,基因改造溶瘤病毒可能成為一種有前景的抗癌療法,預計隨著生物製藥在中國的藥品銷售中的比重穩步提升,未來生物製藥企業將迎來更好的發展機遇。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account